

Olof Gissberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3707788/publications.pdf>

Version: 2024-02-01

11
papers

342
citations

1306789

7
h-index

1281420

11
g-index

11
all docs

11
docs citations

11
times ranked

669
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel Orthogonally Hydrocarbon-Modified Cell-Penetrating Peptide Nanoparticles Mediate Efficient Delivery of Splice-Switching Antisense Oligonucleotides In Vitro and In Vivo. <i>Biomedicines</i> , 2021, 9, 1046.	1.4	6
2	Oligonucleotides Targeting DNA Repeats Downregulate <i>Huntingtin</i> Gene Expression in Huntington's Patient-Derived Neural Model System. <i>Nucleic Acid Therapeutics</i> , 2021, 31, 443-456.	2.0	4
3	Chemical Development of Therapeutic Oligonucleotides. <i>Methods in Molecular Biology</i> , 2019, 2036, 3-16.	0.4	14
4	The ability of locked nucleic acid oligonucleotides to pre-structure the double helix: A molecular simulation and binding study. <i>PLoS ONE</i> , 2019, 14, e0211651.	1.1	7
5	Sugar and Polymer Excipients Enhance Uptake and Splice-Switching Activity of Peptide-Dendrimer/Lipid/Oligonucleotide Formulations. <i>Pharmaceutics</i> , 2019, 11, 666.	2.0	10
6	CTG repeat-targeting oligonucleotides for down-regulating Huntingtin expression. <i>Nucleic Acids Research</i> , 2017, 45, 5153-5169.	6.5	19
7	Fast and efficient synthesis of Zorro-LNA type 3' 5' 3' oligonucleotide conjugates via parallel in situ stepwise conjugation. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 3584-3590.	1.5	4
8	Next-generation bis-locked nucleic acids with stacking linker and 2'-glycylamino-LNA show enhanced DNA invasion into supercoiled duplexes. <i>Nucleic Acids Research</i> , 2016, 44, 2007-2019.	6.5	24
9	Delivery, Effect on Cell Viability, and Plasticity of Modified Aptamer Constructs. <i>Nucleic Acid Therapeutics</i> , 2016, 26, 183-189.	2.0	8
10	Oligonucleotide Therapies: The Past and the Present. <i>Human Gene Therapy</i> , 2015, 26, 475-485.	1.4	220
11	Agammaglobulinemia: causative mutations and their implications for novel therapies. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 1205-1221.	1.3	26